1
Clinical Trials associated with PL-225BAn Open Label Multicentre Phase 1 Study of Oral IGF-1R Inhibitor PL225B in Subjects With Advanced Refractory Solid Tumors.
Clinical study of oral IGF-1R inhibitor PL225B in subjects with advanced refractory solid tumors. The primary objective is to determine the maximum tolerated dose and dose limiting toxicity (ies) of oral IGF-1R inhibitor PL225B in subjects with advanced refractory solid tumors.
100 Clinical Results associated with PL-225B
100 Translational Medicine associated with PL-225B
100 Patents (Medical) associated with PL-225B
100 Deals associated with PL-225B